US FDA approves Krintafel (tafenoquine) for the radical cure of P. vivax malaria
(WorldNews Africa)

Issued: London UK; Philadelphia US; Geneva, Switzerland GSK and Medicines for Malaria Venture (MMV) today announced that the United States Food and Drug Administration (FDA) has approved, under Priority Review, single-dose Krintafel (tafenoquine) for the radical cure (prevention of relapse) of Plasmodium vivax (P. vivax) malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection. Dr. Hal Barron, Chief Scientific Officer and President of Research and Development, GSK, said: `Today`s approval of Krintafel, the first new treatment for Plasmodium vivax malaria in over 60 years, is a significant milestone for people living with this...